Financials

News Discussions Technicals Forecast Seasonals

1541 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to IMMUNEONCO BIOPHARMACEUTICALS (SHAN operating, investing, and financing activities

1541 free cash flow for H2 24 is -8.79 M HKD. For 2024, 1541 free cash flow was -145.94 M HKD and operating cash flow was -134.66 M HKD.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: HKD

TTM

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—